Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study

Agnès Glacet-Bernard, Dagmar Kuhn, Andrew K Vine, Hassiba Oubraham, Gabriel Coscas, Gisèle Soubrane

Abstract

**Aims**—To study the effects of intravitreal tissue plasminogen activator (tPA) in recent onset central retinal vein occlusion (CRVO).

**Methods**—15 patients with recent onset CRVO (from 1–21 days’ duration, mean 8 days) were given 75–100 µg of tPA intravitreally associated with low dose low molecular weight heparin. CRVO was perfused in nine patients and with mild ischaemia not exceeding 100 disc diameters in six patients. Follow up ranged from 5 to 21 months for 14 patients (mean 8 months). Visual acuity measurement, macular threshold (Humphrey perimeter), fluorescein angiography with the scanning laser ophthalmoscope with special emphasis on retinal circulation times, and retinal perfusion were performed at days 0, 1, and 8 and months 1, 3, and 6.

**Results**—Visual acuity was significantly improved on the first day after treatment in only one eye, and decreased transiently in six eyes (40%). Retinal blood velocity was not significantly modified by tPA injection. Retinal ischaemia developed in six eyes (43%), leading to panretinal photocoagulation in five eyes including one with rubecosis iridis. At the end of follow up, visual acuity had improved to 20/30 or better in five eyes (36%), including two with complete recovery; visual acuity was worse than 20/200 in three eyes (28%). No complication of tPA injection was observed.

**Conclusion**—Intravitreal tPA treatment for CRVO appears to be simple and safe, but did not significantly modify the course of the occlusion in our patients immediately after treatment. Final visual outcome did not differ significantly from that observed in the natural course of the disease, but final visual acuity seemed to be slightly better. A randomised study is required to determine if intravitreal tPA actually improves visual outcome in CRVO.

(Please note that the abstract should be the first part of the document and the main body should follow.)

Patients and methods

Fifteen patients were recruited between January 1997 and April 1998 for the study. The major inclusion criteria were the presence of CRVO of recent onset (less than 3 weeks) and a decrease in visual acuity (20/40 or less). CRVO was defined as the presence of retinal haemorrhages in all four quadrants. Diagnosis was always confirmed by fluorescein retinal angiography.

Excluded from the study were patients with late onset CRVO (duration of symptoms of more than 3 weeks); patients with only a slight decrease in visual acuity; patients with CRVO and abnormalities in various haemostatic factors—for example, increased factor VIII, deficiencies of protein C, S, and antithrombin III, activated protein C resistance, etc. These abnormalities of haemostasis may result in a hypercoagulable state and thrombus formation, leading to the occurrence of retinal vein occlusion, or to the development of retinal ischaemia and iris neovascularisation.7–11 A thrombus has also been observed in each case of central retinal vein occlusion (CRVO) in histopathological studies.12 These findings suggest that outflow obstruction is due to thrombosis and that fibrinolytic agents could be an appropriate treatment for retinal vein occlusion. However, thrombus formation as the primary event is always questioned, and the pathogenesis of retinal vein occlusion remains unclear.

Systemic administration of fibrinolytic agents had been performed in small series of CRVO patients.13–17 This treatment showed beneficial effects on retinal blood flow in some cases, but was associated with the risk of massive vitreous haemorrhage and severe systemic complications (cerebral haemorrhage) leading to the termination of some of these studies. Systemic administration of fibrinolytic agents is therefore not recommended in retinal vein occlusion.

Intravitreal administration of fibrinolytic agents, which avoids systemic complications of fibrinolytic therapy, has been evaluated in a pilot study (Lahey et al, presented at the AAO Annual Meeting, Chicago, 1996). This pilot study was designed to evaluate the effects of intravitreal injection of low doses of tissue plasminogen activator (tPA) combined with low molecular weight heparin on ocular status and particularly on retinal blood flow, and its influence on the course of CRVO.
already complicated with anterior or posterior neovascularisation or already treated by laser photoocoagulation; patients with other ocular disorders known to decrease visual acuity (such as uncontrolled glaucoma, cataract, age related macular degeneration, and diabetic retinopathy); pregnant women and children.

The nature of the study was explained to each patient, who were asked to give informed consent, according to the Helsinki-Tokyo declaration. The study protocol was approved by the ethics committee (Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale) of the Henri Mondor hospital.

A complete ophthalmological examination was performed just before the intravitreal injection (day 0), and at days 1, 3, and 6. Examination included ocular and medical history, visual acuity measurement with ETDRS chart, macular threshold testing with the Humphrey perimeter (Carl Zeiss, Le Pecq, France), biomicroscopy, application tonometry, fundus examination, and fluorescein angiography with the scanning laser ophthalmoscope (SLO, Rodenstock), with special emphasis on retinal circulation times and retinal capillary bed evaluation. The retinal transit time was defined as the difference between the laminar venous flow and the arterial flow in the major retinal vessels. Ischaemic areas were measured in disc diameters on central and peripheral fields. Improvement or deterioration in visual acuity was documented as two or more lines of difference on the logarithmic visual acuity chart. Improvement in macular threshold corresponded to an increase of two decibels in the measurement or deterioration in visual acuity was documented as two or more lines of difference on the logarithmic visual acuity chart. Improvement in macular threshold corresponded to an increase of two decibels in the measurement with the Humphrey perimeter. Retinal transit time was considered as improved or deteriorated if it varied by 2 seconds or more.

Intravitreal tPA administration was performed under topical anaesthesia and after local disinfection. tPA (Actilyse, Boehringer Ingelheim, France) was injected into the vitreous cavity with a 30 gauge needle through the pars plana. The dose of tPA was 100 µg in 0.1 ml for the first five patients; the dose was then diminished to 75 µg in 0.075 ml for the 10 next patients, after the report of the possibility of retinal pigment changes, as described by Ruiz LaPuente et al with a 30 µg injection (presented at the AAO annual meeting, San Francisco, 1997). A small anterior chamber paracentesis was often performed before the tPA injection to prevent an increase in intraocular pressure. Low dose subcutaneous low molecular weight heparin (2500 IU per day) was started at the day of tPA treatment and continued for 7 days in order to prevent rethrombosis.

### Results

Pertinent data of the 15 patients included in this study are summarised in Table 1. The ages of the patients ranged from 37 to 74 years (mean 61.5 years); there were 10 (67%) men and five (33%) women. Hypertension was present in six (40%) patients, hyperlipidaemia in six (40%), open angle glaucoma in three (20%), diabetes without retinopathy in one (7%), cardiovascular history in four (27%), positive smoking history in eight (53%, six had stopped smoking, two of them recently, the other four for more than 10 years). Laboratory

### Table 1 Clinical course of CRVO after intravitreal TPA injection, classified from the shorter to the longer duration of symptoms before treatment

<table>
<thead>
<tr>
<th>Case no</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Associated medical conditions</th>
<th>CRVO duration before TPA injection (days)</th>
<th>Dose of TPA</th>
<th>Initial visual acuity</th>
<th>Initial form of CRVO</th>
<th>Visual outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>64</td>
<td>M</td>
<td>Hypertension, smoking, activated protein C resistance, CRVO in the second eye</td>
<td>1</td>
<td>75 µg</td>
<td>20/70</td>
<td>non-ischaemic CRVO</td>
<td>20/20, non-ischaemic CRVO</td>
</tr>
<tr>
<td>2</td>
<td>60</td>
<td>F</td>
<td>Hypercholesterolaemia, glaucoma, HRT</td>
<td>2</td>
<td>100 µg</td>
<td>20/40</td>
<td>non-ischaemic CRVO</td>
<td>CF, ischaemic CRVO, PRP</td>
</tr>
<tr>
<td>3</td>
<td>70</td>
<td>M</td>
<td>Hyperlipidaemia</td>
<td>4</td>
<td>75 µg</td>
<td>20/30</td>
<td>peripheral ischaemic area of 30 DD</td>
<td>20/200, CME, unchanged ischaemic area</td>
</tr>
<tr>
<td>4</td>
<td>69</td>
<td>F</td>
<td>None</td>
<td>5</td>
<td>100 µg</td>
<td>20/400</td>
<td>non-ischaemic CRVO</td>
<td>CF, ischaemic CRVO, PRP, preterinal neovascularisation</td>
</tr>
<tr>
<td>5</td>
<td>58</td>
<td>M</td>
<td>Glaucoma</td>
<td>5</td>
<td>100 µg</td>
<td>20/200</td>
<td>non-ischaemic CRVO</td>
<td>20/125, non-ischaemic CRVO, CME</td>
</tr>
<tr>
<td>6</td>
<td>57</td>
<td>M</td>
<td>Diabetes, stopped smoking</td>
<td>5</td>
<td>75 µg</td>
<td>20/40</td>
<td>non-ischaemic CRVO</td>
<td>20/400, ischaemic CRVO, CME</td>
</tr>
<tr>
<td>7</td>
<td>75</td>
<td>M</td>
<td>Myocardial infarction, hyperlipidaemia, stopped smoking</td>
<td>5</td>
<td>75 µg</td>
<td>20/30</td>
<td>non-ischaemic CRVO</td>
<td>20/70, non-ischaemic CRVO, CME</td>
</tr>
<tr>
<td>8</td>
<td>74</td>
<td>M</td>
<td>Stopped smoking</td>
<td>5</td>
<td>100 µg</td>
<td>20/70</td>
<td>non-ischaemic CRVO</td>
<td>20/15, non-ischaemic CRVO</td>
</tr>
<tr>
<td>9</td>
<td>37</td>
<td>F</td>
<td>Smoking</td>
<td>6</td>
<td>75 µg</td>
<td>20/40</td>
<td>non-ischaemic CRVO</td>
<td>20/25, non-ischaemic CRVO</td>
</tr>
<tr>
<td>10</td>
<td>72</td>
<td>F</td>
<td>Hypertension, overweight, hypercholesterolaemia</td>
<td>8</td>
<td>75 µg</td>
<td>20/40</td>
<td>non-ischaemic CRVO</td>
<td>20/25, non-ischaemic CRVO</td>
</tr>
<tr>
<td>11</td>
<td>72</td>
<td>F</td>
<td>Hypertension, overweight, hypercholesterolaemia</td>
<td>8</td>
<td>100 µg CF</td>
<td>20/50</td>
<td>peripheral ischaemic area of 30 DD</td>
<td>20/40, unchanged ischaemic area, CME</td>
</tr>
<tr>
<td>12</td>
<td>49</td>
<td>M</td>
<td>Hyperlipidaemia, overweight, stopped smoking</td>
<td>14</td>
<td>75 µg</td>
<td>20/160</td>
<td>non-ischaemic CRVO</td>
<td>20/25, non-ischaemic CRVO</td>
</tr>
<tr>
<td>13</td>
<td>61</td>
<td>M</td>
<td>Hypertension, myocardial infarction, stopped smoking</td>
<td>15</td>
<td>75 µg</td>
<td>20/400</td>
<td>peripheral ischaemic area of 20 DD</td>
<td>non-ischaemic CRVO, ruberosis iridis, PRP</td>
</tr>
<tr>
<td>14</td>
<td>67</td>
<td>M</td>
<td>Hypertension, glaucoma, myocardial infarction, hypertension, hyperlipidaemia, angina pectoris, stopped smoking</td>
<td>21</td>
<td>75 µg</td>
<td>20/50</td>
<td>non-ischaemic CRVO</td>
<td>20/20, non-ischaemic CRVO</td>
</tr>
<tr>
<td>15</td>
<td>60</td>
<td>M</td>
<td>Hypertension, glaucoma, myocardial infarction, hypertension, hyperlipidaemia, angina pectoris, stopped smoking</td>
<td>21</td>
<td>75 µg</td>
<td>20/50</td>
<td>non-ischaemic CRVO</td>
<td>20/20, non-ischaemic CRVO</td>
</tr>
</tbody>
</table>

PRP = panretinal photocoagulation; HRT = hormone replacement therapy for postmenopausal woman; DD = disc diameters; CMO = cystoid macular oedema; AO = artery occlusion; CF = counting fingers.
Treatment of recent onset CRVO with intravitreal tissue plasminogen activator

showed a moderate but significant slow down in visual acuity, as shown in Figure 3. Variations of macular threshold (Humphrey perimeter) were grossly similar to those of visual acuity ranging from 20/30 to 20/200 (Fig 1). Panretinal photocoagulation was performed in five eyes and limited peripheral photocoagulation in one eye.

Posterior vitreous detachment probably occurred after treatment in four eyes between days 1 and 7. Posterior vitreous detachment was difficult to ascertain by ocular examination in many cases and data about vitreous status were often questionable.

No complications were observed (no retinal detachment, vitreous haemorrhage, or endophthalmitis) as a result of either the tPA injection.

Figure 1. Distribution of initial and final visual acuity in patients treated by intravitreal tPA injection.

Figure 2. Changes in visual acuity immediately, at 1 week, and at the end of follow up, after tPA injection.

Figure 3. Changes in macular threshold after tPA injection.
or the subcutaneous low molecular weight heparin administration.

No correlation was found between visual acuity improvement and tPA doses (75 or 100 µg), or the time of the injection.

Discussion

Recombinant human tissue type plasminogen activator (tPA) is a relatively clot selective fibrinolytic agent with a molecular weight 70 000 Da. Advantages of tPA over the non-selective fibrinolytic agents (such as streptokinase or urokinase) are its superior results in achieving reperfusion (demonstrated in myocardial infarction), higher efficacy in the lysis of older thrombi, its lack of antigenicity, and its enhanced fibrin selectivity, which leads to greater therapeutic activity. tPA was first successfully administered in ocular surgery to dissolve traumatic hyphaema or postcataract fibrinous membranes.9 Particularly striking was the rapidity of the fibrinolysis with disappearance of all products of fibrin dissolution within 4 hours. Results in treatment of postvitrectomy fibrin formation are controversial.20–22 tPA has been found effective in subretinal haemorrhages related to macular degeneration, either by the intravitreal or subretinal route.21–25 Intravitreal tPA was first tried in CRVO by Lahey et al to attempt to dissolve intravenous thrombi and to avoid systemic complications of intravenous administration of fibrinolytic agents.

In this study, 15 CRVO eyes treated with intravitreal injection of tPA were followed for a mean period of 8 months and underwent ophthalmological examination and fluorescein angiography with the SLO at each visit. Results on the first day and on the first week after the injection are disappointing because, based on previous studies on fibrin dissolution, we had expected a rapid effect on retinal outflow obstruction. A dramatic improvement in visual acuity was observed in only one case immediately after treatment. On the contrary, 40% of the eyes experienced an initial decrease in visual acuity and a slow down in retinal circulation times on fluorescein angiography, but the majority of them returned to their initial level in an 8 day period. One week after treatment, about the fifth of eyes showed an improvement in visual acuity and in retinal circulation times. tPA did not seem then to influence retinal circulation times and visual acuity within the first days of the injection. The transient decrease in visual acuity and retinal circulation times might be explained by a mild inflammatory reaction induced by the injection, but no inflammatory signs, media opacities, or increase in intraocular pressure were observed after treatment.

Our results seem similar to those previously reported by Lahey, using a similar protocol of treatment (intravitreal injection of 65–110 µg of tPA), who described an improvement in visual acuity to 20/40 or better in 33% of the patients followed for 6 months. Thus, tPA injection seems to favourably influence long term visual outcome, but does not improve early signs of CRVO, which was expected in our study.

No correlation was observed between visual outcome and the time of the treatment (Table 1), except for the patient treated on the day of the occurrence of the CRVO, a 64 year old hypertensive man with activated protein C resistance, who had experienced CRVO in the fellow eye 7 years earlier, with poor visual outcome (final visual acuity of 20/200). Improvement in visual acuity observed on the first day persisted with longer follow up, with total recovery at the final visit: final visual acuity was 20/20 in the treated eye. This suggests that tPA injection may be effective within the first hours of the CRVO, or that this treatment is effective only in patients with abnormalities of haemostasis leading to thrombus formation; in the majority of cases with normal haemostasis, the main contributory factor to CRVO is probably hyperviscosity which may not be influenced by fibrinolytic agents.

These findings may explain why intravitreal injection seems less effective than haemodilution therapy, which leads to a dramatic decrease in blood viscosity and rapidly improves retinal circulation times, with long term efficacy on visual acuity.26–28

Good results have also been reported in a pilot study using intra-arterial fibrinolysis in CRVO.29 Urokinase (30 000 IU), delivered into the ophthalmic artery by transfemoral catheterisation, gave a dramatic improvement in visual acuity in 38% of cases, especially when CRVO was associated with delayed arterial retinal filling on fluorescein angiography. These cases of combined central retinal artery and central retinal vein occlusion represent probably a different entity which seems to respond more successfully to fibrinolytic therapy than standard CRVO. Intra-arterial injection would allow fibrinolytic agents to reach the site of the occlusion more efficiently than intravitreal injection. However, the diffusion of tPA though the vitreous gel and its passage through the venous wall remain to be elucidated. The occurrence of posterior vitreous detachment in some of our patients tends to demonstrate that tPA is effective in the vitreous cavity during some hours or days. Lewis recently showed that tPA does not diffuse through the neural retina to reach the subretinal space in the rabbit, but the passage through the venous wall and the presence of tPA at the lamina cribrosa have not yet been analysed.

In this study, no complications occurred after intravitreal injection of tPA, which appeared to be easy and safe. We did not observe retinal pigment changes after injection, as described by Ruiz LaPuent et al. This treatment is also free of contraindications, in contrast with haemodilution or intra-arterial fibrinolysis. However, a randomised trial is needed to establish if intravitreal injection of tPA actually improves visual outcome in CRVO.

The authors have no proprietary interest in any of the materials used in this study.


